GSK’s Epilepsy Drug, Retigabine (Ezogabine/Trobalt/Potiga) To Be Restricted Due To Strange Side Effect


Yet another GSK success story…

http://www.reuters.com/article/2013/05/31/us-glaxosmithkline-trobalt-idUSBRE94U0EP20130531

EU agency calls for curbs on GSK, Valeant epilepsy drug

LONDON | Fri May 31, 2013 5:47am EDT

(Reuters) – Use of an epilepsy drug developed by GlaxoSmithKline and Valeant Pharmaceuticals should be restricted to patients for whom other anti-epileptic medicines have proved inadequate or not tolerated, EU regulators said on Friday.

The European Medicines Agency said the move followed cases of abnormal coloring of the skin, nails, lips and eye tissues, including the retina, in some patients who took Trobalt.

It recommended a comprehensive eye examination should be performed at the start of treatment and at least every six months during treatment. Among 55 patients receiving Trobalt in long-term studies examined so far, 15 had retinal pigmentation, the agency added.

Abnormal coloring of the retina can result in impaired vision.

The Food and Drug Administration issued a similar warning about the drug – which is sold in the United States as Potiga – last month.

(Reporting by Ben Hirschler)

Advertisements

One comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s